Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

著者: Laurence Albigès, Howard Gurney, Vagif Atduev, Cristina Suárez, Miguel Ángel Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Jae‐Lyun Lee, V.P. Stus, Thomas Ferguson, Paweł Wiechno, Erhan Gökmen, Louis Lacombe, Craig Gedye, Rodolfo F. Perini, Manish Sharma, Xiang Peng, Chung‐Han Lee - The Lancet 2023 被引用: 149